| 1 |
2023 |
Margaux Betz, Vincent Massard, Pauline Gilson, Andréa Witz, Julie Dardare, Alexandre Harlé, Jean-Louis Merlin. ESR1 Gene Mutations and Liquid Biopsy in ER-Positive Breast Cancers: A Small Step Forward, a Giant Leap for Personalization of Endocrine Therapy?, Cancers. 2023; 15: 5169.
https://doi.org/10.3390/cancers15215169 |
| 2 |
2024 |
Carmela Dell’Aversana, Federica Sarno, Rosaria Benedetti, Wouter Leonard Megchelenbrink, Donato Cappetta. Cancer Therapy Resistance: Choosing Kinase Inhibitors, Pharmaceutics. 2024; 16: 373.
https://doi.org/10.3390/pharmaceutics16030373 |
| 3 |
2024 |
Dixita Joshi, Janaki Patel, Muskaan Munshi, Zeel Mistry, Alok Prajapati, Asmi Mukherjee, A. V. Ramachandran, Nidarshana Chaturvedi Parashar, Gaurav Parashar, Shafiul Haque, Hardeep Singh Tuli. Hormones as a double-edged sword: the role of hormones in cancer progression and the potential of targeted hormone therapies, Medical Oncology. 2024; 41: 283.
https://doi.org/10.1007/s12032-024-02517-z |
| 4 |
2023 |
Marie Will, Jackson Liang, Ciara Metcalfe, Sarat Chandarlapaty. Therapeutic resistance to anti-oestrogen therapy in breast cancer, Nature Reviews Cancer. 2023; 23: 673.
https://doi.org/10.1038/s41568-023-00604-3 |
| 5 |
2023 |
Andrea K. Corbet, Emmanuel Bikorimana, Raya I. Boyd, Doha Shokry, Kelly Kries, Ayush Gupta, Anneliese Paton, Zhengyang Sun, Zeeshan Fazal, Sarah J. Freemantle, Erik R. Nelson, Michael J. Spinella, Ratnakar Singh. G0S2 promotes antiestrogenic and pro-migratory responses in ER+ and ER- breast cancer cells, Translational Oncology. 2023; 33: 101676101676.
https://doi.org/10.1016/j.tranon.2023.101676 |
| 6 |
2024 |
Camilla Rega, Zuzanna Kozik, Lu Yu, Ifigenia Tsitsa, Lesley-Ann Martin, Jyoti Choudhary. Exploring the Spatial Landscape of the Estrogen Receptor Proximal Proteome With Antibody-Based Proximity Labeling, Molecular & Cellular Proteomics. 2024; 23: 100702100702.
https://doi.org/10.1016/j.mcpro.2023.100702 |
